Syra Health to Deliver Substance Use Disorder and Overdose Prevention Training in Kansas

Rhea-AI Summary

Syra Health Corp. (NASDAQ: SYRA) secures a contract from the Sedgwick County Health Department in Kansas to provide substance use disorder and overdose prevention training. The four-year contract highlights Syra Health's dedication to healthcare education, aiming to equip healthcare professionals, community leaders, and individuals with the necessary knowledge and skills. The training program focuses on stigma reduction, substance use disorder education, and overdose prevention strategies.

CARMEL, Ind., March 21, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today its been awarded a contract from the Sedgwick County Health Department in Kansas to train first responders and community members on substance use disorder and overdose prevention. The four-year contract underscores Syra Health's commitment to healthcare education and training.

Syra Health's comprehensive educational training program is designed for the public safety of the community.  The overall objective of the training is to equip healthcare professionals, community leaders, and individuals with the knowledge and skills necessary to effectively prevent, identify, and manage substance use disorder, using evidence-based practices and innovative approaches. Specifically, Syra Health will provide ongoing, culturally relevant, educational trainings on stigma reduction surrounding substance use disorder, education on substance use disorder itself, and substance overdose prevention strategies.

According to a 2022 National Survey on Drug Use and Health, approximately 17.3% of people aged 12 or older in the United States had a substance use disorder within the past year. This includes 29.5 million individuals with an alcohol use disorder, 27.2 million with a drug use disorder, and 8.0 million people who experienced both an alcohol and drug use disorder. Among young adults aged 18 to 25, nearly 48.8% had either a substance use disorder or a mental illness during the same period.

Dr. Deepika Vuppalanchi, CEO, Syra Health, emphasized the importance of this collaboration, "This contract underscores our shared commitment to addressing this critical public health issue. It's essential to understand the prevalence of substance use disorders in the United States and the strategies that are helping improve health for those on the front line and those in community with one another." 

ABOUT SYRA HEALTH

Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and government. For more information, please visit www.syrahealth.com.

FORWARD-LOOKING STATEMENTS

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Investors should read the risk factors set forth in our registration statement on Form S-1 and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

For more information, please contact:

For Media Inquiries:
Christine Drury
Communications and Marketing Director
Syra Health
463-345-5180
christined@syrahealth.com

For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
shamsian@lythampartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/syra-health-to-deliver-substance-use-disorder-and-overdose-prevention-training-in-kansas-302095879.html

SOURCE Syra Health

FAQ

What contract did Syra Health Corp. (SYRA) secure recently?

Syra Health Corp. secured a contract from the Sedgwick County Health Department in Kansas for substance use disorder and overdose prevention training.

What is the duration of the contract awarded to Syra Health Corp. (SYRA)?

The contract awarded to Syra Health Corp. is for a duration of four years.

What is the focus of Syra Health Corp.'s (SYRA) training program?

The training program by Syra Health Corp. focuses on stigma reduction, substance use disorder education, and overdose prevention strategies.

Who emphasized the importance of the collaboration for Syra Health Corp. (SYRA)?

Dr. Deepika Vuppalanchi, CEO of Syra Health, emphasized the importance of the collaboration for addressing critical public health issues.

What percentage of people aged 12 or older in the US had a substance use disorder according to a 2022 survey?

Approximately 17.3% of people aged 12 or older in the US had a substance use disorder according to a 2022 survey.